Navigation Links
Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
Date:11/9/2010

DUBLIN and MYSTIC, Conn., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 pm UTC/GMT) to discuss selected financial and operating results from the third quarter, including a progress update of the Company's MARINE and ANCHOR trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels in separate patient populations.

The conference call may be heard live via the investor relations section of the Company's website at www.amarincorp.com and will also be available by dialing the following numbers:From outside U.S. dial-in:

(201) 689-8565 From inside U.S. dial-in:

(877) 407-0778Replay will be made available for a period of two weeks following the conference calls. To hear a replay of the call dial 1-201-612-7415 (outside U.S.) 1-877-660-6853 (inside U.S.). For both dial in numbers please use account number is 286 and conference id 359371.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.

Contacts:Investor Contact Information: John F. TheroChief Financial OfficerIn US: +1 (860) 572 4979 investor.relations@amarincorp.comLee M. SternThe Trout GroupIn U.S. +1 (646) 378-2922lstern@troutgroup.comInternational Media Contact Information: Mark Swallow or David DibleCitigate Dewe RogersonIn UK: +44 (0)207 638 9571mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin to Present at UBS Life Sciences Conference
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
4. Baxa Corporation Introduces ExactaMix™ 1200 Automated Compounder for Sterile, Multi-Ingredient Solutions
5. United American Healthcare Corporation Announces Senior Management Appointments and Relocation to Chicago
6. Luminex Corporation Reports Third Quarter 2010 Results
7. Gentris Corporation Names New Chief Scientific Advisor
8. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
9. DURECT Corporation Announces Third Quarter 2010 Financial Results
10. Techne Corporation Declares Dividend
11. Pharmos Corporation Reports 2010 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of the ... Forecast" report to their offering. ... Proton Therapy Market in Italy will ... There are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton ...
(Date:3/29/2017)... 2017  The Global Health Innovative Technology Fund ... to battle infectious diseases around the globe, today ... could help deliver a range of new innovative ... This latest round of targeted support ... testing a pediatric formulation of a drug considered ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 2017 , ... This morning, more than 275 medical doctors, ... for an independent Vaccine Safety Commission. Five of the signers of the letter, ... a press conference at 9:00 AM Friday, March 31 at the National ...
(Date:3/29/2017)... Georgia (PRWEB) , ... March 29, 2017 , ... Full ... Therilus, founder of Pet Protect Law that assists dog owners in creating ... assist new owners in taking the natural next step to protect their new companion. ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
Breaking Medicine News(10 mins):